Temozolomide and targeted therapy against epidermal growth factor receptor in glioma

被引：0

作者：

Daianu, Oana ^{[1
]}

Georgescu, Ada Maria ^{[1
]}

Ciurea, Marius Eugen ^{[2
]}

Alexandru, Oana ^{[1
]}

Artene, Stefan-Alexandru ^{[1
]}

Tataranu, Ligia Gabriela ^{[3
]}

Purcaru, Oana Stefana ^{[1
]}

Tache, Daniela Elise ^{[1
]}

Danciulescu, Maria-Mihaela ^{[4
]}

Taisescu, Oana ^{[5
]}

Folcuti, Roxana ^{[1
]}

Dricu, Anica ^{[1
]}

机构：

[1] Univ Med & Pharm Craiova, Biochem Unit, Craiova, Romania

[2] Univ Med & Pharm Craiova, Dept Plast & Reconstruct Surg, Craiova, Romania

[3] Bagdasar Arseni Emergency Hosp, Dept Neurosurg, Bucharest, Romania

[4] Univ Med & Pharm Craiova, Dept Oncol, Fac Med, Craiova, Romania

[5] Univ Med & Pharm Craiova, Unit Anat, Craiova, Romania

来源：

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | 2016年 / 9卷 / 08期

关键词：

EGFR; temozolomide; glioblastoma; combined therapy; synergy; PHASE-II TRIAL; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; RADIATION-THERAPY; BRAIN-TUMORS; EGF RECEPTOR; BEVACIZUMAB; EXPRESSION; IRINOTECAN; CELLS;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Gliomas represent a heterogeneous group of diseases difficult to diagnose and even more difficult to treat. Intrinsic or acquired resistance to Temozolomide (TMZ) treatment is a common feature of both low- and high-grade glioma and is the major reason for therapeutic failure. The aim of this study is to improve the response to TMZ by blocking the Epithelial Growth Factor Receptor (EGFR) activity in glioma cells. GB1B and AC1B glioma cell lines used in this study were low passage cultures established from fresh tissues obtained from consented glioma patients undergoing surgery. Cell viability was quantified by hemocytometer cell counting, using trypan blue. Interactions between TMZ and EGFR inhibitor were classified by the Multiplicative Model. We found that TMZ treatment and inhibition of EGFR activity by AG556 suppressed tumor growth in glioblastoma and astrocytoma cells, but their co-administration induced additive and synergistic cell death in astrocytoma, whereas the treatment failed to elicit synergistic cytotoxicity in glioblastoma cells.

引用

页码：15249 / 15261

页数：13

共 43 条

[21]

MCKEEVER PE, 1987, AM J PATHOL, V127, P358

[22] A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy [J].

Moller, Soren ;

Grunnet, Kirsten ;

Hansen, Steinbjorn ;

Schultz, Henrik ;

Holmberg, Mats ;

Sorensen, Morten ;

Poulsen, Hans S. ;

Lassen, Ulrik .

ACTA ONCOLOGICA, 2012, 51 (06) :797-804

[23] How does the immune system attack cancer? [J].

Morse, MA ;

Lyerly, HK ;

Clay, TM ;

Abdel-Wahab, O ;

Chui, SY ;

Garst, J ;

Gollob, J ;

Grossi, PM ;

Kalady, M ;

Mosca, PJ ;

Onaitis, M ;

Sampson, JH ;

Seigler, HF ;

Toloza, EM ;

Tyler, D ;

Vieweg, J ;

Yang, YP .

CURRENT PROBLEMS IN SURGERY, 2004, 41 (01) :9-132

[24]

Nagane M, 1996, CANCER RES, V56, P5079

[25] ANTITUMOR IMIDAZOTETRAZINES .26. PHASE-I TRIAL OF TEMOZOLOMIDE (CCRG-81045, M-AND-B 39831, NSC-362856) [J].

NEWLANDS, ES ;

BLACKLEDGE, GRP ;

SLACK, JA ;

RUSTIN, GJS ;

SMITH, DB ;

STUART, NSA ;

QUARTERMAN, CP ;

HOFFMAN, R ;

STEVENS, MFG ;

BRAMPTON, MH ;

GIBSON, AC .

BRITISH JOURNAL OF CANCER, 1992, 65 (02) :287-291

[26] Genetic pathways to primary and secondary glioblastoma [J].

Ohgaki, Hiroko ;

Kleihues, Paul .

AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (05) :1445-1453

[27] Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma [J].

Peters, Katherine B. ;

Lou, Emil ;

Desjardins, Annick ;

Reardon, David A. ;

Lipp, Eric S. ;

Miller, Elizabeth ;

Herndon, James E., II ;

McSherry, Frances ;

Friedman, Henry S. ;

Vredenburgh, James J. .

ONCOLOGIST, 2015, 20 (07) :727-728

[28] Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma [J].

Prados, Michael D. ;

Chang, Susan M. ;

Butowski, Nicholas ;

DeBoer, Rebecca ;

Parvataneni, Rupa ;

Carliner, Hannah ;

Kabuubi, Paul ;

Ayers-Ringler, Jennifer ;

Rabbitt, Jane ;

Page, Margaretta ;

Fedoroff, Anne ;

Sneed, Penny K. ;

Berger, Mitchel S. ;

McDermott, Michael W. ;

Parsa, Andrew T. ;

Vandenberg, Scott ;

James, C. David ;

Lamborn, Kathleen R. ;

Stokoe, David ;

Haas-Kogan, Daphne A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) :579-584

[29] Phase II trial of temozolomide in patients with progressive low-grade glioma [J].

Quinn, JA ;

Reardon, DA ;

Friedman, AH ;

Rich, JN ;

Sampson, JH ;

Provenzale, JM ;

McLendon, RE ;

Gururangan, S ;

Bigner, DD ;

Herndon, JE ;

Avgeropoulos, N ;

Finlay, J ;

Tourt-Uhlig, S ;

Affronti, ML ;

Evans, B ;

Stafford-Fox, V ;

Zaknoen, S ;

Friedman, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :646-651

[30] A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy [J].

Raizer, Jeffrey J. ;

Abrey, Lauren E. ;

Lassman, Andrew B. ;

Chang, Susan M. ;

Lamborn, Kathleen R. ;

Kuhn, John G. ;

Yung, W. K. Alfred ;

Gilbert, Mark R. ;

Aldape, Kenneth A. ;

Wen, Patrick Y. ;

Fine, Howard A. ;

Mehta, Minesh ;

DeAngelis, Lisa M. ;

Lieberman, Frank ;

Cloughesy, Timothy F. ;

Robins, H. Ian ;

Dancey, Janet ;

Prados, Michael D. .

NEURO-ONCOLOGY, 2010, 12 (01) :95-103

← 1 2 3 4 5 →